Why Statins Are Fuelling a Silent Dementia Crisis, While Big Pharma Keeps Quiet
Examining the hidden link between statins, brain health, and the rise of dementia worldwide.
I lost my dad to dementia four years ago, on February 1, 2022. That experience changed everything for me. I have been sitting on this piece for years, unsure whether to release it. Recent events, and the memories they stirred, made it clear that now was the time.
Only yesterday, I joined a livestream for the funeral of a family member in Melbourne, Australia, someone who, like my dad, was taken by statins and ultimately, dementia. Another vivacious, caring, generous soul lost to Big Pharma. Distance prevented me from attending in person, but watching the service, and having a heartfelt conversation with her eldest son afterwards, brought back memories of my own experience and compelled me to finally publish this.
I don’t belong to the medical establishment, though I did study pharmacology and physiology at university, and perhaps that’s exactly why I’m willing to ask the questions everyone else avoids. Everything I know started with lived experience: watching my father decline after years on statins, seeing the same pattern in relatives, and quickly realising no one in the system bothered to explain why. That silence didn’t just anger me, it pushed me into my own research, because someone had to look deeper.
My dad had been on statins for more than six years, prescribed for “cholesterol lowering”, long before any memory problems showed. Watching his slow decline still feels like a wound that never heals. In our family, the same tragedy touched aunties and uncles. Many of them came from older Greek and Italian migrant communities in Australia, communities that, increasingly, are bearing the brunt of the dementia epidemic in the country. If you’re reading this, understand that most of these migrants never had formal education and were raised to treat anyone in a white coat as unquestionable. Doctors, pharmacists, the entire medical system — they were seen as kings. They trusted every word, even when their own children warned them to slow down and question more.
That kind of blind faith made them easy targets for a Big Pharma machine that counts on people never pushing back.
Dementia is no longer some distant future risk: it is very much a crisis in our lives and our communities. And it’s not just in Australia, it’s a global phenomenon.
So I was completely taken by surprise when, today - Friday, 14 November 2025 - I read a headline about a recent Australian Bureau of Statistics (ABS) report confirming something deeply troubling: dementia has overtaken heart disease as the leading cause of death in Australia, with more than 17,500 deaths in 2024. Was the universe nudging me to finally shout the truth from the rooftops?
Many of those were among people aged over 75, but the trend is unmistakable: dementia is not just a disease of old age, but of a system that has failed to ask hard questions about its causes.
As someone for whom dementia has hit home, I believe we must face an urgent and uncomfortable possibility: the rise in dementia may be significantly linked to our widespread use of statins. I don’t offer that lightly, and certainly not without lived experience pushing me to say it. This isn’t a throwaway line for attention, and it’s not designed to shock anyone. It’s the conclusion I reached after years of watching what happened in my own family, questioning what I was told, and digging for answers the system never provided. This is not to deny that statins have helped millions with cardiovascular disease, but to demand that we reckon with what might be the unintended cost to the brain. This is not to deny that statins have helped millions with cardiovascular disease, but to demand that we reckon with what might be the unintended cost to the brain.
The Brain And It’s Relationship With Cholesterol
I’m not going to get too technical here so bear with me.
The majority of the brain’s total cholesterol (between 70–90%) is found in the myelin sheath that insulates nerve fibres. Myelin is critical for the efficient transmission of electrical signals.
Although an immense amount of knowledge has accumulated concerning regulation of cholesterol homeostasis in the body, it does not include the brain, where details are just emerging. Approximately 25% of the total amount of the cholesterol present in humans is localised to the brain, most of it present in myelin. Almost all brain cholesterol is a product of local synthesis, with the blood-brain barrier efficiently protecting it from exchange with lipoprotein cholesterol in the circulation.
What does this mean in everyday language?
Your brain makes almost all of its own cholesterol. It does this because the brain needs cholesterol to build and maintain cells, send signals and keep its own systems stable. The body cannot simply send cholesterol from the bloodstream into the brain. A protective wall known as the blood brain barrier help stop that exchange. Certain drugs, though, depending on their structure, can pass through and influence what happens inside the brain.
Think of the blood brain barrier as a strict security checkpoint. It checks what enters. It only lets in what the brain specifically needs. Cholesterol in your blood stays on the outside. Cholesterol inside your brain comes from the brain itself. In most situations, that separation holds.
This matters because it shows how separate the brain’s chemistry is from the rest of the body. A drug or food that changes cholesterol in the blood may not work the same way inside the brain. And that’s where problems begin when introducing statins into the body to help aid in cardiovascular support.
So, why does the brain build its own supply instead of using what the body already has? In simple terms, it needs a steady, reliable amount to keep nerve cells working. It cannot risk sudden shifts that happen in the bloodstream.
What Are Statins?
Statins are a class of medications used to lower cholesterol by reducing the amount the liver produces and increasing the liver’s ability to remove cholesterol from the blood. They are the most common medicine prescribed for high cholesterol and can lower “bad” LDL cholesterol and triglycerides while potentially increasing “good” HDL cholesterol.
They work by blocking an enzyme in the liver that’s needed to make cholesterol. By reducing cholesterol production in the liver, they also improve the liver’s ability to remove LDL cholesterol that is already in your bloodstream.
Medical lesson over.
A Global Epidemic with a Modern History
To understand how dramatically dementia has emerged, we need to look at history. In the mid-20th century, dementia was not the public-health catastrophe we see today. Life expectancy was much lower, and many did not live into the ages where dementia becomes common.
Yet by 1990, dementia cases worldwide numbered in the millions, and projected to soar: a landmark prevalence study estimated 25 million people with dementia in 2000, rising to 63 million by 2030.
Statins entered mainstream clinical use in the late 1980s and wider adoption across cardiovascular care accelerated through the 1990s, as additional drugs in the class were approved. Coincidence?
The history of dementia is not one of an ancient, inevitable scourge. While age-related cognitive decline was recognised in antiquity, clinical dementia as we understand it - Alzheimer’s, vascular dementia, Lewy-body dementia - became clearly defined only in the 20th century.
Dementia is not just an accident of ageing, it is a human cost of modern medicine and Big Pharma’s relentless pursuit of profit.
If my research has shown me anything, it’s this: cholesterol is the brain’s lifeblood.
I’ll reiterate again: our brains are cholesterol-rich in a way few realise. Cholesterol is a key component of myelin and synaptic membranes. It supports neurotransmission, plasticity, and neuronal repair. Severe disruption of cholesterol in the central nervous system impairs function.
Several researchers argue that, in principle, lowering cholesterol too aggressively, especially in people whose brain cholesterol homeostasis is sensitive, could undermine neuronal health.
The Double-Edged Sword
If you’ve read this far, then you will know that statins are drugs designed to lower cholesterol in the blood, and for many people with cardiovascular issues, they do that well. But the brain is a bit different; it makes almost all its own cholesterol, which it needs to work properly. Some statins can sneak past the brain’s protective barrier more easily than others. When that happens, they can interfere with the brain’s own cholesterol production.
In animal studies, long-term use of these statins reduced cholesterol in areas of the brain important for memory. The result? Problems with learning and remembering. The good news: when the drugs were stopped, memory improved, showing the effect can be reversible.
Cholesterol in the brain also helps cells clean up damaged or “misfolded proteins”. If cholesterol levels drop too much, this cleanup slows down, which could let harmful proteins build up, a process thought to contribute to dementia.
Big Pharma, Medicine, and the Marriage of Convenience
Why has this potential risk been largely overlooked, and who’s responsible?
Pharmaceutical industry incentives: Statins have been blockbuster drugs for decades. Profit machines. The benefit to cardiovascular health is clear and well-established; the profit motive to maintain broad prescription is enormous. Industry-funded studies are more likely to emphasise cardiovascular endpoints than long-term neurologic outcomes.
Regulatory complacency: The FDA in the U.S. did issue a safety communication in 2012, noting reversible memory loss and confusion in patients on statins. But it framed these as mild, non-serious, and reversible, not a cause for broad reevaluation. Well, that’s a convenient narrative when a $56.7 Billion industry (cardiovascular disease) is on the line.
Clinical focus on heart, not brain: In cardiology guidelines, preventing heart attacks often trumps concerns about uncertain cognitive side effects. Physicians may be reluctant to question statins, especially when stopping them is perceived as increasing risk of cardiovascular events. Add the influence of Big Pharma’s incentives, and you start to see why so many stay quiet.
Underreporting and diagnosis bias: Memory complaints may not be reported by carers of patients, or when they are, may be conveniently dismissed by doctors as “normal ageing.” And once cognitive decline becomes irreversible, statins are not typically suspected.
Conveniently, this protects an industry focused more on profits than patients. After all, a cured patient is a lost customer, that’s Big Pharma’s mantra, right?
If Big Pharma and the medical establishment aren’t actively suppressing data, hard as that may be to believe even after the global CV19 debacle, there is still a systemic failure. They simply haven’t built the monitoring systems needed to track long-term cognitive effects in real-world, diverse populations. Intentional, perhaps?
The Stakes: My Family, My Community, Our Future
In my Greek-Australian and Italian-Australian circles, I see too many stories like my father’s. Elderly relatives, burdened with vascular risk or “high cholesterol” factors, started on statins, and years later, severe memory problems appeared. Could we have seen what was coming? Could a different conversation, about risk, type of statin, long-term follow-up, have altered the outcome?
Despite my repeated attempts to warn my family about the risks of long-term statin use, and despite my objection to placing my father in a home, the decision moved ahead. On the day he was meant to be admitted, I took his hand, walked him out and drove him straight home, knowing it could cost him his place in the facility. In the end, his decline became too rapid for my elderly mother to manage, and he was placed there anyway. I never wanted to put that weight on her.
I’ve also noticed ethnic-oriented care facilities in Australia, promoted as ‘aged care,’ where a strikingly high percentage of residents are dementia patients. These facilities do offer essential support for families struggling to cope, yet they also exist as highly profitable enterprises. Whether their creation was purely benevolent or driven by profit, the reality is that communities are paying a heavy human and financial cost.
We Need to Act
Clinical awareness and patient agency
Doctors must proactively monitor cognition in patients on statins, particularly older adults or those who report memory concerns.
Patients and families should be informed: statin therapy carries meaningful cognitive risks, and alternatives (or adjustments) might exist, for example, reconsidering the dose or need.
Research reform
We need long-term, independent cohort studies tracking cognition, brain imaging, and cholesterol metabolism in statin-treated patients.
Randomised controlled trials should stratify by statin type (lipophilic vs hydrophilic), dose, duration, and patient genotype.
Funders (public health bodies, governments) must invest in mechanistic research on how statins affect brain cholesterol, myelin, and protein clearance.
Public health policy
Dementia prevention frameworks must consider drug safety and the psychiatric–neurologic long-term effects of widely used drugs, not just lifestyle risk factors.
Guidelines for statin prescription, particularly for primary prevention in older adults, should be revisited in light of both cardiovascular and cognitive risk–benefit balances.
I will not sit silently while dementia is dismissed as inevitable collateral damage in the so-called war on cholesterol — a war built on fear, misinformation, and the profits of Big Pharma. I believe the link between statins and dementia is strong enough, biologically plausible enough, and personally devastating enough to demand systemic change.
My role now is painfully clear: I must convince my siblings to take my elderly mother off the same statins that stole my father’s life, and with it, the man we all loved. Every day, I feel the weight of what could happen if we fail.
If you or someone you love is on a statin and you’re worried, please don’t ignore it. Speak to your healthcare professional. Ask whether the statin makes sense long-term, and whether there’s room for monitoring or, at the very least, modification. Share your story. Your experience matters, and it may help trigger the kind of collective awareness that can drive real reform.
For me, all I know is that my father deserved better.
--------
References
Meta-analysis of 55 observational studies on statin use and dementia risk PubMed
Meta-analysis of 46 observational studies, statin type, and potency OUP Academic
Cochrane systematic review of RCTs in Alzheimer’s disease cochranelibrary.com
Narrative review on lipophilicity and cognitive effects PubMed
Animal study: simvastatin reduces hippocampal cholesterol and impairs memory PubMed
Biomolecular model: cholesterol depletion and neuroserpin aggregation arxiv.org
Ginkgo Evaluation of Memory Study: statins and dementia risk PubMed
Six-year outpatient cohort (Australia): statins and memory decline PubMed
Framingham Heart Study incidence trends over decades PubMed
Global burden of dementia (GBD) 2021 BioMed Central
Historical prevalence and the forgotten past of dementia PubMed
This article is based on personal experience and research. It is not intended as medical advice. Always consult a qualified healthcare professional regarding any treatment decisions.